Under the terms of the deal, Agenus has granted NewVac an exclusive license to manufacture, market and sell Oncophage as well as pursue a development program of Oncophage in combination with NewVac’s co-adjuvant technology in the Russian Federation and CIS countries.
Agenus will receive a transfer price and royalties upon Oncophage product sales, and potential milestone payments.
Oncophage is approved in Russia for the treatment of renal cell carcinoma in patients who have intermediate risk of recurrence.